Advanced Aerosol Generation.
Engineered for Inhaled Therapeutics.
Next-generation aerosol technologies enabling precise, efficient delivery across small molecules, biologics, and emerging modalities.
Up to 90% respirable fraction • Low-shear biologics • Digital breath actuation.
Pneuma’s core competency is advanced aerosol generation.
We engineer droplet size, respirable fraction, and formulation compatibility to enable efficient deep-lung delivery—including low-shear delivery of fragile biologics—supported by digitally enabled dosing and adherence features.
Precise Delivery.
Advanced Therapies. Unprecedented.
Pneuma’s aerosol platform enables precise pulmonary delivery to improve outcomes while reducing systemic exposure. Built for broad formulation compatibility—from small molecules to fragile biologics—our technology supports both respiratory and systemic programs.
Capabilities:
Precision droplet control to target regions of the lung
High respirable fraction for efficient delivery
Low-shear delivery to protect fragile biologics
Digital breath actuation + dose verification to support adherence
Example applications:
• Asthma, COPD, and other lung disorders
• Oncology and other inhaled biologic programs
• Emerging modalities
Drug delivery comparison
Broad and Highly Protected
Patent Portfolio
Pneuma’s extensive IP estate includes 50+ issued patents and 130+ pending, protecting our breakthrough technology across multiple therapeutic applications.
Comprehensive Coverage
Our patent portfolio protects key functions and features that enhance safety, health outcomes, formulations, control, and user experience. Pneuma’s patent portfolio protects core aerosol generation methods that are difficult to replicate through conventional nebulization or mesh-based approaches.
Therapeutic Aerosol Platform for Pulmonary Drug Delivery
Pneuma’s Norway platform is a pulmonary delivery system built on advanced aerosol generation physics. It enables low-shear delivery of fragile biologics and high-efficiency deposition of small-molecule therapies through precise, breath-actuated aerosol control.
Digitally enabled features, including voice guidance, dose verification, and data connectivity, support consistent use, dosing confidence, and real-world adherence.
Key Platform Capabilities:
Low-Shear Aerosol Generation
Preserves the structural integrity of fragile biologics and complex formulations.
Precision Droplet Control
Tunable aerosol characteristics enable targeting of specific regions of the lung.
High Respirable Fraction
Achieves up to 90% lung deposition, improving delivery efficiency.
Breath-Actuated, Propellant-Free Dosing
Ensures consistent, patient-synchronized delivery.
Digital Guidance & Verification
Voice prompts, dose confirmation, and Bluetooth™ connectivity support adherence and clinical insight.
High-Dose Confidence Mode
Designed to ensure full dose delivery and enable physician oversight.
Non-Small Cell Lung Cancer Research
Pneuma’s pharmaceutical platform is designed to transform how inhaled therapies are delivered, especially for lung diseases and systemic conditions. Our low-shear ejector technology ensures that large-molecule biologics, such as recombinant proteins and other complex drugs, are delivered without denaturation, preserving their efficacy. This technology supports deep lung penetration with precise, consistent dosing for a wide range of treatments.
A major focus is our collaboration with a leading U.S. cancer research center to develop inhaled therapies for non-small cell lung cancer (NSCLC) and precancerous conditions.. By delivering biologics directly to the lungs—such as licensed checkpoint inhibitors from Leads Biolabs, Inc.—we aim to enhance the efficacy of cancer treatment and address precancerous conditions.
Key Highlights
Oncology – Advancing targeted inhaled therapies for non-small cell lung cancer and precancerous conditions..
Low-Shear Technology – Preserves the structure of large-molecule biologics during delivery.
Direct Lung Delivery – Optimized for biologics to maximize therapeutic impact.
Proprietary Platform – Enables precise, efficient treatment tailored for respiratory and systemic conditions.
Combination Potential – Can be used as a standalone therapy treating precancerous conditions or in combination with systemic treatments for NSCLC.
This platform is unlocking new possibilities for targeted drug delivery, offering hope for improved outcomes in cancer care and other critical health conditions.
Pioneering the future of drug delivery through significant scientific advances in aerosol technology.
Pneuma’s technology is reshaping pharmaceutical delivery, offering a new paradigm for inhaled therapeutics. Our platform's ability to more effectively deliver small molecules and to deliver large-molecule biologics, including recombinant proteins and complex therapies, without denaturation represents a major step forward in the field. Studies demonstrate the platform's high lung penetration and precise dosing which contribute to enhanced therapeutic efficacy and safety. These findings highlight the potential to improve treatment outcomes for conditions like asthma, COPD, and non-small cell lung cancer.